ES2062174T3 - Derivados de alfa-amino carboxamida n-fenilalquil-sustituidos y procedimiento para su preparacion. - Google Patents

Derivados de alfa-amino carboxamida n-fenilalquil-sustituidos y procedimiento para su preparacion.

Info

Publication number
ES2062174T3
ES2062174T3 ES90109950T ES90109950T ES2062174T3 ES 2062174 T3 ES2062174 T3 ES 2062174T3 ES 90109950 T ES90109950 T ES 90109950T ES 90109950 T ES90109950 T ES 90109950T ES 2062174 T3 ES2062174 T3 ES 2062174T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
substituted
zero
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90109950T
Other languages
English (en)
Inventor
Philippe Dostert
Paolo Pevarello
Franco Heidempergher
Mario Varasi
Alberto Bonsignori
Romeo Roncucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898912071A external-priority patent/GB8912071D0/en
Priority claimed from GB909007567A external-priority patent/GB9007567D0/en
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Application granted granted Critical
Publication of ES2062174T3 publication Critical patent/ES2062174T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/02—Monothiocarboxylic acids
    • C07C327/04—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/06—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

El uso de un compuesto de fórmula (I) (I) donde R es alquilo de C1-C8; cicloalquilo de C3-C8, un anillo de furilo, tienilo o piridilo; o un anillo de fenilo sin sustituir o sustituido por 1 a 4 sustituyentes seleccionados independientemente entre halógeno, alquilo de C1-C6, alcoxi de C1-C6 y trif luorometilo; A esun grupo-(CH2)mó -(CH2)p-X-(CH2)qdonde m es un entero de 1 a 4, uno entre p y q es cero y el otro es cero o un entero de1 a 4 y X es-O-, -S-o -NR4en el que R4 es hidrógeno o alquilo de C1-C4; n es cero o 1; cada uno de entre R1 y R2, independientemente, es hidrógeno o alquilo de C1-C4; R3 es hidrógeno, alquilo de C1-C4 sin sustituir o sustituido por hidroxi o por un anillo de fenilo opcionalmente sustituido por 1 a 4 sustituyentes seleccionados independientemente entre halógeno, alquilo de C1-C6, alcoxi de C1-C6 y trifl uorometilo; R''3 es hidrógeno; o R3 y R''3 tomados juntos con el átomo de carbono adyacente forman un anillo de cicloalquilo de C3-C6; cada uno de R5 y R6 es, independientemente, hidrógeno o alquilo de C1-C6; y cuando R es alquilo de C1-C6, entonces A es un grupo -(CH2)p-X-(CH2)qen el que p y q son ambos cero y X es tal como se ha definido antes; o una sal farmacéuticamente aceptable del mismo, en la preparación de una composición farmacéutica para utilizarla como agente anti-epiléptico, anti-Parkinson, neuroprotector, antidepresivo, antiespástico y/o hipnótico.
ES90109950T 1989-05-25 1990-05-25 Derivados de alfa-amino carboxamida n-fenilalquil-sustituidos y procedimiento para su preparacion. Expired - Lifetime ES2062174T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898912071A GB8912071D0 (en) 1989-05-25 1989-05-25 N-phenylalkyl substituted-alpha-amino carboxamide derivatives and process for their preparation
GB909007567A GB9007567D0 (en) 1990-04-04 1990-04-04 New n-substituted alpha-amino carboxamide derivatives and process for their preparation

Publications (1)

Publication Number Publication Date
ES2062174T3 true ES2062174T3 (es) 1994-12-16

Family

ID=26295400

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90109950T Expired - Lifetime ES2062174T3 (es) 1989-05-25 1990-05-25 Derivados de alfa-amino carboxamida n-fenilalquil-sustituidos y procedimiento para su preparacion.

Country Status (23)

Country Link
US (3) US5236957A (es)
EP (2) EP0400495B1 (es)
JP (1) JP2771328B2 (es)
KR (1) KR0179661B1 (es)
CN (1) CN1027588C (es)
AT (1) ATE96775T1 (es)
AU (1) AU645752B2 (es)
CA (1) CA2033190C (es)
CZ (1) CZ281420B6 (es)
DE (1) DE69004337T2 (es)
DK (1) DK0400495T3 (es)
ES (1) ES2062174T3 (es)
FI (1) FI114792B (es)
HU (2) HUT55348A (es)
IE (1) IE63934B1 (es)
IL (1) IL94466A (es)
MY (1) MY105618A (es)
NO (1) NO179944C (es)
NZ (1) NZ233785A (es)
PT (1) PT94160B (es)
RU (1) RU2097371C1 (es)
WO (1) WO1990014334A1 (es)
YU (1) YU48322B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
EP0666840A1 (en) * 1993-08-30 1995-08-16 Otsuka Pharmaceutical Co., Ltd. Benzylamine derivatives
SE9303274D0 (sv) * 1993-10-07 1993-10-07 Astra Ab Novel phenylethyl and phenylproplamines
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
IT1283489B1 (it) * 1996-07-23 1998-04-21 Chiesi Farma Spa Ammidi di alfa-amminoacidi,loro preparazione e loro impiego terapeutico
FR2753967B1 (fr) * 1996-09-27 1998-11-27 Sod Conseils Rech Applic Nouveaux derives de la phenoxyethylamine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1998047869A1 (en) 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
CA2306024C (en) * 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
WO2000061188A1 (en) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
DE10049822B4 (de) * 1999-11-03 2005-12-22 Siemens Ag Verfahren zur Darstellung eines Untersuchungsobjektes unter Verwendung von Schnittbildern
US6306911B1 (en) * 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
SI1423168T1 (sl) 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
US6667327B2 (en) * 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
JP4675108B2 (ja) * 2002-11-26 2011-04-20 ハーキュリーズ・インコーポレーテッド 可溶性の会合性カルボキシメチルセルロース、その製造方法およびその用途
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
JP2006515326A (ja) 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US6979750B1 (en) 2003-04-18 2005-12-27 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
ATE411027T1 (de) 2003-10-23 2008-10-15 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
EP1533295A1 (en) * 2003-11-24 2005-05-25 Newron Pharmaceuticals S.p.A. Cyclopentyl Derivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
CA2571505A1 (en) * 2004-06-23 2006-01-05 F. Hoffmann-La Roche Ag New mao-b inhibitors
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US20080096965A1 (en) * 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1963280B1 (en) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
DK2474521T3 (en) * 2006-06-19 2016-10-31 Newron Pharm Spa High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
KR20090034365A (ko) * 2006-07-28 2009-04-07 알콘 리서치, 리미티드 외부 망막 질환을 치료하는데 유용한 모노아민 산화효소 저해제
KR100868353B1 (ko) * 2007-03-08 2008-11-12 한국화학연구원 도파민 ｄ4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
DK2155663T3 (en) 2007-06-15 2018-01-22 Newron Pharm Spa SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS
KR101593627B1 (ko) 2007-12-11 2016-02-11 뉴론 파마슈티칼즈 에스. 피. 에이. 고순도의 ２­［４­（３­ 또는 ２­플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
CA2707646C (en) 2007-12-19 2016-09-13 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
JP5746612B2 (ja) 2008-03-19 2015-07-08 オーリムメッド・ファルマ・インコーポレーテッド 中枢神経系疾患および障害の治療に有効な新規化合物
US9212155B2 (en) * 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
NZ602648A (en) 2010-04-27 2014-10-31 Newron Pharm Spa Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
KR101679568B1 (ko) 2014-10-02 2016-11-28 한국과학기술연구원 알파-아미노아미드 유도체 화합물 및 이를 포함하는 약학적 조성물
CA2963371C (en) 2014-10-02 2020-06-02 Korea Institute Of Science And Technology Alpha-aminoamide derivative compound and pharmaceutical composition containing the same
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN112153968A (zh) 2017-10-05 2020-12-29 生物基因公司 制备α-羧酰胺吡咯烷衍生物的工艺
EP3762364B1 (en) 2018-03-08 2023-08-23 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
CN112041296B (zh) * 2018-04-28 2023-12-29 上海璃道医药科技有限公司 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途
CN108997163A (zh) * 2018-07-18 2018-12-14 华东理工大学 含苯并脂肪环结构的氨基乙酰胺类化合物及其用途
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
ES2977486T3 (es) 2019-08-06 2024-08-26 Medichem Sa Proceso para preparar safinamida
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
GB8409015D0 (en) * 1984-04-06 1984-05-16 Eschem Ltd Binding
DE3416693A1 (de) * 1984-05-05 1985-11-07 Bayer Ag, 5090 Leverkusen Verfahren zur behandlung von cellulosischen fasermaterialien
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4715619A (en) * 1986-01-13 1987-12-29 Printmark, Inc. Book jacket
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives

Also Published As

Publication number Publication date
CA2033190A1 (en) 1990-11-26
YU48322B (sh) 1998-05-15
HU905133D0 (en) 1991-04-29
HU211550A9 (en) 1995-12-28
DE69004337T2 (de) 1994-02-24
EP0400495B1 (en) 1993-11-03
IE901878L (en) 1990-11-25
NO179944B (no) 1996-10-07
FI114792B (fi) 2004-12-31
RU2097371C1 (ru) 1997-11-27
DE69004337D1 (de) 1993-12-09
JPH04500215A (ja) 1992-01-16
NO179944C (no) 1997-01-15
IE63934B1 (en) 1995-06-28
ATE96775T1 (de) 1993-11-15
US5391577A (en) 1995-02-21
AU5729990A (en) 1990-12-18
US5502079A (en) 1996-03-26
NO910270D0 (no) 1991-01-23
WO1990014334A1 (en) 1990-11-29
CN1027588C (zh) 1995-02-08
KR920701131A (ko) 1992-08-11
CZ281420B6 (cs) 1996-09-11
NZ233785A (en) 1992-12-23
CA2033190C (en) 2003-04-08
HUT55348A (en) 1991-05-28
EP0426816A1 (en) 1991-05-15
PT94160A (pt) 1991-01-08
NO910270L (no) 1991-01-23
DK0400495T3 (da) 1993-12-06
CZ252090A3 (en) 1996-06-12
PT94160B (pt) 1997-04-30
AU645752B2 (en) 1994-01-27
FI910354A0 (fi) 1991-01-23
YU102290A (sh) 1992-07-20
IL94466A0 (en) 1991-03-10
JP2771328B2 (ja) 1998-07-02
CN1047496A (zh) 1990-12-05
IL94466A (en) 1995-01-24
KR0179661B1 (ko) 1999-05-15
EP0400495A1 (en) 1990-12-05
MY105618A (en) 1994-11-30
US5236957A (en) 1993-08-17

Similar Documents

Publication Publication Date Title
SE9702799D0 (sv) New compounds
ATE317378T1 (de) Triphenylalkenderivate und ihre anwendung als selektive modulatoren des östrogenrezeptors
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AR035522A1 (es) Compuestos derivados de fenol, composiciones farmaceuticas, su uso y metodo de tratamiento
UA72917C2 (en) Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
YU48322B (sh) Derivati alfa-aminokarboksamida supstituisani n-fenilalkilom i postupak za njihovo pripremanje
PT91126A (pt) Processo para a preparacao de derivados de (1-hidroxi-2-piperidinil-alquil)-2- indolonas, 2-quinoleinonas, benzo {b}-2-azepinonas, 2-benzimidazolonas e 2- -quinazolinonas e de composicoes farmaceuticas que os contem
SE7908995L (sv) Heterocykliska foreningar
DE69505968D1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
SE9703377D0 (sv) New compounds
SE9703378D0 (sv) New compounds
CO4230234A1 (es) DERIVADOS DE 6-(HIDROXIFENIL)SULFONIL-BENZO[b]PIRANO, COMPO- SICIONES QUE CONTIENEN TALES DERIVADOS, USOS DE LOS MISMOS, PROCEDIMIENTOS DE PREPARACION E INTERMEDIOS EMPLEADOS EN LA PREPARACION DE TALES DERIVADOS
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
ES2015621A6 (es) Un metodo para preparar compuestos cuaternarios de enamina.
JPS5748948A (en) Propanol amine derivative
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
FR1602627A (en) 3 omega-subst alkyl indoles
AR012209A1 (es) Derivados terapeuticos de naftaleno, formulaciones farmaceuticas de los mismos, procesos para su preparacion y su uso en medicina
SE8104508L (sv) Ergolinderivat, sett att framstella dessa, farmaceutiska kompositioner innehallande desamma och anvendning derav vid terapeutisk behandling
FR2840304B1 (fr) Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique
AR011136A1 (es) Compuesto derivado 4-aminoalcoxi-1h-benzoimidazoles, composicion farmaceutica que lo contiene y el uso del mismo para la fabricacion de unmedicamento
SE8803484D0 (sv) Nya kinolin- och isokinolinderivat och foerfarande foer framstaellning daerav
NZ218030A (en) 3-imino-2,3-dihydropyridazine derivatives and pharmaceutical compositions
AR011137A1 (es) Derivados de 4-aminoetoxiindazol, su uso para la preparacion de un medicamento y composiciones farmaceuticas que los contienen
AR011139A1 (es) 4-aminoalcoxi-1,3-dihidro-benzoimidazol-2-tionas, su uso en la preparacion de un medicamento y composicion farmaceutica que los contiene

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 400495

Country of ref document: ES